Methasan (Methadone Hydrochloride)

Methadone hydrochloride acts as a full agonist at the mu‑opioid receptors in the brain and spinal cord. By activating these receptors, it produces analgesia and reduces the physiological response to opioid withdrawal, while its long half‑life allows stable plasma concentrations with once‑daily dosing.

The appropriate dose of Methasan is determined individually by a qualified prescriber based on the patient’s clinical condition, prior opioid exposure, and response to therapy. Dosage adjustments are made according to therapeutic goals and safety monitoring.

Safety data for methadone use in pregnancy and lactation are limited. Methadone may cross the placenta and be present in breast milk, so clinicians must weigh potential benefits against risks. Treatment decisions should be made by a healthcare professional familiar with the patient’s obstetric history.

To order Methasan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methasan (methadone) offers a long half‑life that enables once‑daily dosing, which can improve adherence compared with shorter‑acting opioids. Unlike buprenorphine, methadone is a full mu‑opioid agonist, providing stronger analgesia but requiring careful monitoring for respiratory depression and cardiac effects.

Methasan should be stored at ambient temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight and heat sources. Ensure the packaging remains sealed until use to maintain product integrity.

Methasan is supplied as an oral formulation and is taken by mouth. The tablet (or liquid, if provided) should be swallowed whole with water, unless the prescriber advises an alternative method such as crushing for patients with swallowing difficulties.

The most serious risks include respiratory depression, especially during dose initiation or when combined with other depressants, and cardiac arrhythmias such as QT interval prolongation. Patients should be monitored for signs of severe sedation, breathing difficulties, or abnormal heart rhythms.

Methasan is contraindicated in patients with known hypersensitivity to methadone, those with severe respiratory insufficiency, uncontrolled asthma, or significant cardiac conduction disorders. Caution is also advised for individuals with severe hepatic impairment or who are taking interacting medications listed under major interactions.